Aurelio Maggio

List of Publications by Year
in descending order

171 papers	5,001 citations	87888 38 h-index	118850 62 g-index
171 all docs	171 docs citations	171 times ranked	3764 citing authors

#	Article	IF	Citations
1	The safety and effectiveness of deferiprone in a largeâ€scale, 3â€year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	2.5	192
2	Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Journal of Magnetic Resonance Imaging, 2006, 23, 662-668.	3.4	173
3	Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial. Blood Cells, Molecules, and Diseases, 2002, 28, 196-208.	1.4	165
4	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	2.5	147
5	Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, 96, 41-47.	3.5	129
6	LACK OF EVIDENCE OF PERMANENT ENGRAFTMENT AFTER IN UTERO FETAL STEM CELL TRANSPLANTATION IN CONGENITAL HEMOGLOBINOPATHIES1. Transplantation, 1996, 61, 1176-1179.	1.0	121
7	StandardizedT2* map of normal human heartin vivo to correctT2* segmental artefacts. NMR in Biomedicine, 2007, 20, 578-590.	2.8	119
8	Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. European Journal of Haematology, 2006, 76, 183-192.	2.2	115
9	Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. Journal of Magnetic Resonance Imaging, 2009, 30, 62-68.	3.4	115
10	A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nature Biotechnology, 2006, 24, 89-94.	17.5	114
11	The risks of early cordocentesis (12â€“21 weeks): Analysis of 500 procedures. Prenatal Diagnosis, 1990, 10, 425-428.	2.3	86
12	Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells, Molecules, and Diseases, 2009, 42, 247-251.	1.4	85
13	Guideline recommendations for heart complications in thalassemia major. Journal of Cardiovascular Medicine, 2008, 9, 515-525.	1.5	84
14	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	1.4	79
15	Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in Î²-thalassemia intermedia patients. Free Radical Research, 2001, 34, 529-540.	3.3	77
16	Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. European Heart Journal Cardiovascular Imaging, 2018, 19, 299-309.	1.2	74
17	MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease.. American Journal of Roentgenology, 1999, 173, 1477-1480.	2.2	73
18	Light and shadows in the iron chelation treatment of haematological diseases. British Journal of Haematology, 2007, 138, 407-421.	2.5	73

#	Article	IF	Citations
19	Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart, 2009, 95, 1688-1693.	2.9	73
20	The significance of the hemoglobin A2 value in screening for hemoglobinopathies. Clinical Biochemistry, 2009, 42, 1786-1796.	1.9	72
21	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	2.5	69
22	Longâ€term sequential deferiproneâ€“deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. British Journal of Haematology, 2009, 145, 245-254.	2.5	68
23	Intestinal Permeability and Genetic Determinants in Patients, First-Degree Relatives, and Controls in a High-Incidence Area of Crohn's Disease in Southern Italy. American Journal of Gastroenterology, 2005, 100, 2730-2736.	0.4	66
24	A Prospective Study of Hepatocellular Carcinoma Incidence in Thalassemia. Hemoglobin, 2006, 30, 119-124.	0.8	66
25	Significance of borderline hemoglobin A2 values in an Italian population with a high prevalence of Â-thalassemia. Haematologica, 2008, 93, 1380-1384.	3.5	66
26	Safe mobilization of CD34+ cells in adults with Î²-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood, 2014, 123, 1483-1486.	1.4	62
27	2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood, 2015, 126, 89-93.	1.4	62
28	Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major. Circulation: Cardiovascular Imaging, 2015, 8, e003230.	2.6	62
29	Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. Blood, 1997, 90, 2207-12.	1.4	62
30	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells, Molecules, and Diseases, 2011, 47, 166-175.	1.4	50
31	Therapeutic Options for Patients with Severe Î²-Thalassemia: The Need for Globin Gene Therapy. Human Gene Therapy, 2007, 18, 1-9.	2.7	48
32	The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the majorâ€intermedia dichotomy?. British Journal of Haematology, 2017, 176, 124-130.	2.5	47
33	IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica, 2012, 97, 679-686.	3.5	46
34	Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells, Molecules, and Diseases, 2010, 45, 136-139.	1.4	45
35	Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study. Blood, 2018, 131, 263-265.	1.4	45
36	Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. British Journal of Haematology, 2010, 150, 245-247.	2.5	44

#	Article	IF	Citations
37	The spectrum of Î²-thalassaemia mutations in Sicily. British Journal of Haematology, 1988, 69, 393-397.	2.5	44
38	Sickle hemoglobinopathies in sicily. American Journal of Hematology, 1990, 33, 81-85.	4.1	41
39	Desensitization to hydroxycarbamide following longâ€term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. British Journal of Haematology, 2010, 151, 509-515.	2.5	41
40	Pattern of complications and burden of disease in patients affected by beta thalassemia major. Current Medical Research and Opinion, 2017, 33, 1525-1533.	1.9	40
41	The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major. British Journal of Haematology, 2017, 178, 676-688.	2.5	39
42	Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematology,the, 2020, 7, e469-e478.	4.6	39
43	Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. Journal of Medical Virology, 1992, 38, 200-206.	5.0	38
44	Regional and global pancreatic T*₂ MRI for iron overload assessment in a large cohort of healthy subjects: Normal values and correlation with age and gender. Magnetic Resonance in Medicine, 2011, 65, 764-769.	3.0	38
45	Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Human Genetics, 1995, 95, 526-530.	3.8	37
46	Oxidation resistance of LDL is correlated with vitamin E status in Î²-thalassemia intermedia. Atherosclerosis, 1998, 137, 429-435.	0.8	37
47	Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5â€year longâ€term <scp>I</scp>talian multicenter randomized clinical trial. American Journal of Hematology, 2015, 90, 634-638.	4.1	35
48	Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease andÎ²-Thalassemia Patients. Hemoglobin, 2015, 39, 225-229.	0.8	34
49	Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2000, 25, 135-141.	2.4	33
50	New analytical tools and epidemiological data for the identification of HbA2 borderline subjects in the screening for beta-thalassemia. Bioelectrochemistry, 2008, 73, 137-140.	4.6	33
51	The genetic heterogeneity of Î²-globin gene defects in Sicily reflects the historic population migrations of the island. Blood Cells, Molecules, and Diseases, 2011, 46, 282-287.	1.4	32
52	Analysis of delta-globin gene alleles in the Sicilian population: identification of five new mutations. Haematologica, 2006, 91, 1681-4.	3.5	32
53	Potential Myocardial Iron Content Evaluation by Magnetic Resonance Imaging in Thalassemia Major Patients Treated with Deferoxamine or Deferiprone During a Randomized Multicenter Prospective Clinical Study. Hemoglobin, 2003, 27, 63-76.	0.8	31
54	Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. American Journal of Hematology, 2005, 78, 158-159.	4.1	31

#	Article	IF	Citations
55	Longâ€term use of deferiprone significantly enhances leftâ€ventricular ejection function in thalassemia major patients. American Journal of Hematology, 2012, 87, 732-733.	4.1	30
56	Clinical and Hematological Response to Hydroxyurea in a Patient with Hb Leporbp-Thalassemia. Hemoglobin, 1997, 21, 219-226.	0.8	29
57	Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in Î²â€thalassemia. Annals of the New York Academy of Sciences, 2010, 1202, 52-58.	3.8	29
58	Chelation treatment in sickleâ€cellâ€anaemia: much ado about nothing?. British Journal of Haematology, 2011, 154, 545-555.	2.5	29
59	Influence of myocardial fibrosis and blood oxygenation on heart T2* values in thalassemia patients. Journal of Magnetic Resonance Imaging, 2009, 29, 832-837.	3.4	28
60	Human coelomic fluid investigation: A MS-based analytical approach to prenatal screening. Scientific Reports, 2018, 8, 10973.	3.3	28
61	Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. British Journal of Haematology, 2006, 133, 105-106.	2.5	27
62	Iron deficiency does not compromise the diagnosis of high HbA2 Â thalassemia trait. Haematologica, 2012, 97, 472-473.	3.5	26
63	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	3.5	25
64	National networking in rare diseases and reduction of cardiac burden in thalassemia major. European Heart Journal, 2022, 43, 2482-2492.	2.2	25
65	External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clinical Chemistry and Laboratory Medicine, 2007, 45, 88-92.	2.3	24
66	Current challenges in the management of patients with sickle cell disease â€“ A report of the Italian experience. Orphanet Journal of Rare Diseases, 2019, 14, 120.	2.7	24
67	Î²A and Î²thal DNA haplotypes in Sicily. Human Genetics, 1986, 72, 229-230.	3.8	23
68	The Role of CARD15 Mutations and Smoking in the Course of Crohn's Disease in a Mediterranean Area. American Journal of Gastroenterology, 2008, 103, 649-655.	0.4	23
69	Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients. Journal of Cardiovascular Medicine, 2015, 16, 689.	1.5	23
70	CLINICAL AND HEMATOLOGICAL RESPONSES TO HYDROXYUREA IN SICILIAN PATIENTS WITH Hb S/Î²-THALASSEMIA. Hemoglobin, 2001, 25, 9-17.	0.8	22
71	Successful application of preimplantation genetic diagnosis for beta-thalassaemia and sickle cell anaemia in Italy. Human Reproduction, 2002, 17, 1158-1165.	0.9	22
72	Incidence of Crohnâ€™s disease and CARD15 mutation in a small township in Sicily. European Journal of Epidemiology, 2007, 21, 887-892.	5.7	22

#	Article	IF	Citations
73	Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients. Hemoglobin, 2011, 35, 206-216.	0.8	21
74	HEPATIC SICKLING. Transplantation, 1999, 67, 65-68.	1.0	21
75	Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia IntermediaVersusThalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients. Hemoglobin, 2008, 32, 97-107.	0.8	20
76	Incidence of haemoglobinopathies in Sicily: the impact of screening and prenatal diagnosis. International Journal of Clinical Practice, 2015, 69, 1129-1138.	1.7	20
77	Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation. Bone Marrow Transplantation, 1996, 18, 637-9.	2.4	20
78	Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Haematologica, 2006, 91, 1420-1.	3.5	20
79	Rapid detection of six common Mediterranean and three non-Mediterranean ?-thalassemia point mutations by reverse dot blot analysis. American Journal of Hematology, 2003, 74, 191-195.	4.1	19
80	Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia major. Blood Cells, Molecules, and Diseases, 2013, 51, 85-88.	1.4	19
81	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	4.1	19
82	Cerebrovascular events in sickle cellâ€beta thalassemia treated with hydroxyurea: A single center prospective survey in adult Italians. American Journal of Hematology, 2013, 88, E261-4.	4.1	18
83	Quantification of <scp>HBG</scp> m<scp>RNA</scp> in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and betaâ€thalassemia. European Journal of Haematology, 2014, 92, 66-72.	2.2	18
84	Lentiviral globin gene therapy with reduced-intensity conditioning in adults with Î²-thalassemia: a phase 1 trial. Nature Medicine, 2022, 28, 63-70.	30.7	18
85	Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. Blood Cells, Molecules, and Diseases, 2014, 53, 265-271.	1.4	17
86	Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18). Cancer Genetics and Cytogenetics, 1992, 58, 71-75.	1.0	16
87	Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia.. Gut, 1993, 34, S142-S143.	12.1	16
88	The Sea Urchin sns5 Insulator Protects Retroviral Vectors From Chromosomal Position Effects by Maintaining Active Chromatin Structure. Molecular Therapy, 2009, 17, 1434-1441.	8.2	16
89	Feasibility of DNA diagnosis of haemoglobinopathies on coelocentesis. British Journal of Haematology, 2011, 153, 268-272.	2.5	16
90	Embryoâ€fetal erythroid cell selection from celomic fluid allows earlier prenatal diagnosis of hemoglobinopathies. Prenatal Diagnosis, 2016, 36, 375-381.	2.3	16

#	Article	IF	Citations
91	Evidence for a Globin Promoter-Specific Silencer Element Located Upstream of the Human Î´-Globin Gene. Biochemical and Biophysical Research Communications, 1994, 204, 413-418.	2.1	15
92	Left Ventricular Diastolic Dysfunction in Î²-Thalassemia Major with Heart Failure. Hemoglobin, 2018, 42, 68-71.	0.8	15
93	Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia. Blood, 1998, 92, 3936-42.	1.4	15
94	Nucleated red blood cells and soluble transferrin receptor in thalassemia syndromes: relationship with global and ineffective erythropoiesis. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1539-42.	2.3	14
95	The International Hemoglobinopathy Research Network (<scp>INHERENT</scp>): An international initiative to study the role of genetic modifiers in hemoglobinopathies. American Journal of Hematology, 2021, 96, E416-E420.	4.1	14
96	Reliability of EMA Binding Test in the Diagnosis of Hereditary Spherocytosis in Italian Patients. Acta Haematologica, 2011, 125, 136-140.	1.4	13
97	Identification of embryoâ€“fetal cells in celomic fluid using morphological and shortâ€tandem repeats analysis. Prenatal Diagnosis, 2016, 36, 973-978.	2.3	13
98	In utero fetal liver hematopoietic stem cell transplantation: is there a role for alloreactive T lymphocytes?. Blood, 2000, 96, 1608-1609.	1.4	13
99	Analytical evaluation of the Tosoh HLC-723 G7 automated HPLC analyzer for hemoglobin A2 and F determination. Clinical Biochemistry, 2005, 38, 159-165.	1.9	12
100	The Italian multiregional thalassemia registry: Centers characteristics, services, and patientsâ€™ population. Hematology, 2016, 21, 415-424.	1.5	12
101	CMR for myocardial iron overload quantification: calibration curve from the MIOT Network. European Radiology, 2020, 30, 3217-3225.	4.5	12
102	Quantitative evaluation of oxidative stress status on peripheral blood in beta-thalassaemic patients by means of electron paramagnetic resonance spectroscopy. British Journal of Haematology, 2005, 131, 135-140.	2.5	11
103	Hb Marineo [Î²70(E14)Alaâ†'Val]: A Silent Hemoglobin Variant with a Mutation Within the Heme Pocket. Hemoglobin, 2006, 30, 139-148.	0.8	11
104	Mosaic segmental uniparental isodisomy and progressive clonal selection: a common mechanism of late onset Â-thalassemia major. Haematologica, 2013, 98, 691-695.	3.5	11
105	Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. Digestive and Liver Disease, 2016, 48, 650-655.	0.9	11
106	alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Haematologica, 1992, 77, 502-6.	3.5	11
107	Induction of gamma-globin gene transcription by hydroxycarbamide in primary erythroid cell cultures from Lepore patients. British Journal of Haematology, 2008, 141, 720-727.	2.5	10
108	Î²-Thalassemia heterozygote state detrimentally affects health expectation. European Journal of Internal Medicine, 2018, 54, 76-80.	2.2	10

#	Article	IF	Citations
109	Longitudinal followâ€up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study. British Journal of Haematology, 2020, 191, 107-114.	2.5	10
110	Independent clinical trials. Lancet, The, 2004, 363, 1080.	13.7	9
111	Embryoâ€fetal erythroid megaloblasts in the human coelomic cavity. Journal of Cellular Physiology, 2010, 225, 385-389.	4.1	9
112	Serial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac death. Blood Cells, Molecules, and Diseases, 2013, 50, 241-246.	1.4	9
113	Realâ€life experience with liver iron concentration <scp>R</scp>2 <scp>MRI</scp> measurement in patients with hemoglobinopathies: baseline data from <scp>LICNET</scp>. European Journal of Haematology, 2016, 97, 361-370.	2.2	9
114	Population pharmacokinetics and dosing recommendations for the use of deferiprone in children younger than 6Âyears. British Journal of Clinical Pharmacology, 2017, 83, 593-602.	2.4	9
115	Cardiac involvement by CMR in different genotypic groups of thalassemia major patients. Blood Cells, Molecules, and Diseases, 2019, 77, 1-7.	1.4	9
116	Hemoglobin Phenotype and Mean Erythrocyte Volume in Sicilian People. Acta Haematologica, 1984, 71, 214-214.	1.4	8
117	Cardiac complications in thalassemia: noninvasive detection methods and new directions in the clinical management. Expert Review of Cardiovascular Therapy, 2003, 1, 439-452.	1.5	8
118	Study on hydroxyurea response in hemoglobinopathies patients using genetic markers and liquid erythroid cultures. Hematology Reports, 2016, 8, 6678.	0.8	8
119	Coâ€heredity of silent <scp>CAP</scp> + 1570 T>C (<scp>HBB</scp>:c*96T>C) defect and severe Î²â€thal mutation: a cause of mild Î²â€thalassemia intermedia. International Journal of Laboratory Hematology, 2016, 38, 17-26.	1.3	8
120	Fetal aneuploidy diagnosed at celocentesis for early prenatal diagnosis of congenital hemoglobinopathies. Acta Obstetricia Et Gynecologica Scandinavica, 2018, 97, 312-321.	2.8	8
121	Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. International Journal of Molecular Sciences, 2018, 19, 681.	4.1	8
122	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	2.5	8
123	Allele-specific transcription of fetal genes in primary erythroid cell cultures from Lepore and ÎÎ²Â° thalassemia patients. Experimental Hematology, 2005, 33, 1363-1370.	0.4	7
124	Functional characterization of the sea urchin sns chromatin insulator in erythroid cells. Blood Cells, Molecules, and Diseases, 2005, 35, 339-344.	1.4	7
125	Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. British Journal of Haematology, 2011, 154, 659-661.	2.5	7
126	Identification of three new nucleotide substitutions in the Î²â€globin gene: laboratoristic approach and impact on genetic counselling for betaâ€thalassaemia. European Journal of Haematology, 2014, 92, 444-449.	2.2	7

#	Article	IF	Citations
127	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	2.5	7
128	A Region Upstream of the Human Î´-Globin Gene Shows a Stage-Specific Interaction with Globin Promoters in Erythroid Cell Lines. Blood Cells, Molecules, and Diseases, 2001, 27, 874-881.	1.4	5
129	HCV Clearance Among Hemophiliacs and Beta-Thalassemics. Gastroenterology, 2007, 132, 1634.	1.3	5
130	IL-23R determines susceptibility in CrohnÊ¼s disease in a mediterranean area. Inflammatory Bowel Diseases, 2009, 15, 317-318.	1.9	5
131	Coâ€inheritance of the rare Î² hemoglobin variants Hb Yaounde, Hb GÃ¶rwihl and Hb City of Hope with other alterations in globin genes: impact in genetic counseling. European Journal of Haematology, 2015, 94, 322-329.	2.2	5
132	Longitudinal changes in <scp>LIC</scp> and other parameters in patients receiving different chelation regimens: Data from <scp>LICNET</scp>. European Journal of Haematology, 2018, 100, 124-130.	2.2	5
133	Deferiprone Versus Sequential Deferiprone-Deferoxamine Treatment in Thalassemia Major: A Five Years Multicenter Randomized Clinical Trial under the Auspices of the Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE).. Blood, 2007, 110, 575-575.	1.4	5
134	Treatment with hydroxyurea and iron chelation therapy in patients with hemoglobinopathies. European Journal of Haematology, 2005, 75, 267-269.	2.2	4
135	Typing of the immunological system in human embryos by coelocentesis. European Journal of Haematology, 2007, 79, 435-438.	2.2	4
136	Hb Southern Italy: coexistence of two missence mutations (the Hb Sun Prairie Î±₂ 130 Ala â†') Tj ETQq0 0 0 rgBT /Overlock Haematology, 2008, 143, 138-142.	2.5	4
137	Glucose 6â€phosphate dehydrogenase Palermo R257M: a novel variant associated with chronic nonâ€spherocytic haemolytic anaemia. British Journal of Haematology, 2010, 149, 296-297.	2.5	4
138	The Sea Urchinsns5Chromatin Insulator Shapes the Chromatin Architecture of a Lentivirus Vector Integrated in the Mammalian Genome. Nucleic Acid Therapeutics, 2016, 26, 318-326.	3.6	4
139	Coinheritance of a Rare Nucleotide Substitution on theÎ²-Globin Gene and Other Known Mutations in the Globin Clusters: Management in Genetic Counseling. Hemoglobin, 2016, 40, 231-235.	0.8	4
140	The heterozygote state for Î²â€thalassemia detrimentally affects health outcomes. American Journal of Hematology, 2017, 92, E23-E25.	4.1	4
141	Longâ€term sequential deferiprone and deferasirox therapy in transfusionâ€dependent thalassaemia patients: a prospective clinical trial. British Journal of Haematology, 2019, 186, e209-e211.	2.5	4
142	IN UTERO HAEMATOPOIETIC STEM CELL TRANSPLANTATION (IUHSCT). Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009031.	1.3	4
143	Very early prenatal diagnosis of Cockayneâ€™s syndrome by coelocentesis. Journal of Obstetrics and Gynaecology, 2022, , 1-8.	0.9	4
144	An element upstream from the human Î´-globin-encoding gene specifically enhances Î²-globin reporter gene expression in murine erythroleukemia cells. Gene, 1996, 168, 237-241.	2.2	3

#	Article	IF	Citations
145	Incidence of Pulmonary Hypertension in Haemoglobinopathic Patients without Left Ventricular Disfunction.. Blood, 2005, 106, 2691-2691.	1.4	3
146	Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study. Blood Transfusion, 2021, 19, 168-176.	0.4	3
147	Celomic Fluid: Laboratory Workflow for Prenatal Diagnosis of Monogenic Diseases. Molecular Diagnosis and Therapy, 2022, 26, 239-252.	3.8	3
148	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.5	3
149	The Regulation of ?-Globin Gene Expression. Annals of the New York Academy of Sciences, 1990, 612, 160-166.	3.8	2
150	Non-Transfusion-Dependent Thalassemia: A Complex Mix of Genetic Entities Yet to Be Fully Discovered. BioMed Research International, 2015, 2015, 1-2.	1.9	2
151	Granulocyteâ€“Colony Stimulating Factor plus Plerixafor in Patients with Î²-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ Cells with Specific Gene Expression Profile. Thalassemia Reports, 2017, 7, 6392.	0.5	2
152	Evaluation of IPF counting on Mindray BCâ€6800 hematology analyzer. International Journal of Laboratory Hematology, 2016, 38, e89-92.	1.3	2
153	Hb San Cataldo [Î²144(HC1)Lysâ†'Thr;HBB: C.434Aâ€‰>â€‰C]: A New Hemoglobin Variant with Increased Affinity for Oxygen. Hemoglobin, 2016, 40, 223-227.	0.8	2
154	HBB: c.316-125A>G and HBB: c.316-42delC: Phenotypic Evaluations of Two Rare Changes in the Second Intron of the HBB Gene. Hemoglobin, 2017, 41, 234-238.	0.8	2
155	Early prenatal diagnosis of Hb Lepore Bostonâ€Washington and Î²â€thalassemia on fetal celomatic DNA. International Journal of Laboratory Hematology, 2022, 44, 796-802.	1.3	2
156	The use of hydroxyurea in the real life of MIOT network: an observational study. Expert Opinion on Drug Safety, 2022, , 1-8.	2.4	2
157	Co-inheritance of Hb Hershey [Î²70(E14) Alaâ†'Gly] and Hb La Pommeraie [Î²133(H11)Valâ†'Met] in a Sicilian subject. European Journal of Haematology, 2010, 84, 453-457.	2.2	1
158	Role of iron metabolism genetic determinants in response to chelation therapy in a cohort of Î²-thalassemia and sickle cell syndromes Italian patients. Thalassemia Reports, 2014, 4, .	0.5	1
159	Efficacy of Ruxolitinib as Inducer of Fetal Hemoglobin in Primary Erythroid Cultures from Sickle Cell and Beta-Thalassemia Patients. Thalassemia Reports, 2019, 9, 8101.	0.5	1
160	Long-Term Outcome of Iron-Induced Cardiac Disease in Patients with Thalassemia Major Treated with Combined DFP/DFO or DFO Alone.. Blood, 2006, 108, 1764-1764.	1.4	1
161	Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	0
162	Iron load. Thalassemia Reports, 2013, 3, 5.	0.5	0

#	Article	IF	Citations
163	Development and recent progresses of gene therapy for Î²-thalassemia. Thalassemia Reports, 2014, 4, .	0.5	0
164	New Codanin-1 Gene Mutations in a Italian Patient with Congenital Dyserythropoietic Anemia Type I and Heterozygous Beta-Thalassemia. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 278-281.	0.6	0
165	Phenotypic Evaluation of a Novel Nucleotide Substitution (HBD: c.442T>C) on the Î´-Globin Gene. Hemoglobin, 2017, 41, 220-222.	0.8	0
166	Co-inheritance of HBB:c.â^'106Gâ€‰>â€‰C, a rare single nucleotide variation at position â^'56 relative to transcription initiation site, with other known mutations in the globin clusters. Hematology, 2018, 23, 368-372.	1.5	0
167	Phenotypic evaluations of HBB:c.93-23T>C, a nucleotide substitution in the IVS I nt 108 of Î²-globin gene. Journal of Clinical Pathology, 2018, 71, 298-302.	2.0	0
168	Double Heterozygosity for Hb Durham-N.C. (HBB: c.344T>C) [Î²114(G16)Leuâ†'Pro] and the IVS-I-110 (HBB: c.93-21G>A) Causing a Severe Î²-Thalassemia Phenotype. Hemoglobin, 2019, 43, 210-213.	0.8	0
169	Therapeutic Options for Patients with Severe?-Thalassemia: The Need for Globin Gene Therapy. Human Gene Therapy, 2006, .	2.7	0
170	Multislice Multiecho T2* Cardiovascular Magnetic Resonance Detects Heterogeneous Myocardial Iron Distribution in Thalassemia Patients. Blood, 2008, 112, 3877-3877.	1.4	0
171	Magnetic Resonance T2* Technique for Segmental and Global Quantification of Myocardial Iron : Multi-Centre Validation in the MIOT (Myocardial Iron Overload in Thalassemia) Network. Blood, 2008, 112, 5420-5420.	1.4	0